Using chlorhexidine-silver sulfadiazine-impregnated venous catheters may lead to fewer catheter-related blood stream infections and lower central-venous catheter related costs, according to a study in the American Journal of Infection Control.
Researchers found patients with CHSS-catheters experienced zero CRBSIs per 1,000 patient days, while patients with standard catheters experienced 5.01 CRBSIs per 1,000 patient days.
Additionally, CHSS-catheters were associated with a lower CVC-related cost per day than standard catheters, at $5.21 and $10.03 (converted from Euros), respectively.
Researchers concluded CHSS-catheters led to reduced CRBSIs and lower costs.
More Articles on Infection Control:
Stethoscopes: New Culprit in MRSA Transmission
CDC: New Vancomycin-resistant Strep Strains Have Appeared
To Prevent MRSA, Healthcare Workers Want Clarified Protocols